Drug approvals rarely mark the end of regulatory oversight. Many medicines reach the market with known risks that require careful monitoring and risk management. Regulators therefore rely on post-approval safety frameworks to protect patients while ensuring access to important therapies.

One of the most significant of these frameworks in the United States is the Risk Evaluation and Mitigation Strategy (REMS) program administered by the U.S. Food and Drug Administration (FDA). REMS programs aim to ensure that the benefits of a medication outweigh its risks when those risks remain serious or complex.

Since gaining authority through the Food and Drug Administration Amendments Act of 2007 (FDAAA), the agency has implemented hundreds of REMS programs to manage safety risks associated with certain prescription medicines.

As of 2025:

The FDA has approved more than 300 REMS programs since 2008.
Approximately 73 REMS programs remain active.
Roughly 94–91% of these programs include strict safe-use requirements, known as Elements to Assure Safe Use.

For pharmaceutical companies, REMS programs represent both a regulatory requirement and a complex operational challenge. They require coordinated compliance, monitoring systems, patient education, and reporting obligations.

This article explains how REMS programs work, why regulators require them, and how companies implement compliant risk-mitigation systems.

What Is a REMS Program?

A Risk Evaluation and Mitigation Strategy (REMS) is a safety program required by the FDA for certain medications with serious safety concerns. The purpose of REMS is to ensure that a drug’s therapeutic benefits continue to outweigh its potential risks.

Unlike standard drug labeling, REMS programs require specific risk-management actions beyond routine prescribing information.

These programs may include:

Patient education materials
Provider training requirements
Restricted distribution systems
Patient monitoring protocols
Registries and data reporting systems

In other words, REMS programs function as structured public-health interventions designed to reduce medication-related harm.

Why REMS Programs Exist

Drug development involves careful risk-benefit evaluation. Some medicines treat severe or life-threatening conditions but also carry significant risks.

Examples include drugs that may cause:

Birth defects
Life-threatening infections
Severe psychiatric effects
Organ toxicity
Addiction or misuse

In these situations, regulators must balance two priorities:

Ensuring patient access to effective therapies
Preventing avoidable harm

REMS programs address that challenge by imposing targeted safety controls.

Public-health context

Adverse drug events represent a major healthcare burden.

Research shows medication-related complications contribute to:

Millions of emergency department visits annually
Significant hospitalizations among older adults
Substantial healthcare costs

These risks justify proactive safety frameworks such as REMS.

Legislative and Regulatory Foundations

The REMS framework emerged from growing concern about post-market drug safety.

The FDA Amendments Act of 2007

Congress granted the FDA authority to require REMS through the Food and Drug Administration Amendments Act (FDAAA).

This law allowed regulators to require risk-mitigation programs when:

A medication presents serious safety concerns
Standard labeling alone cannot adequately manage those risks

Since then, REMS programs have become a central component of the FDA’s pharmacovigilance strategy.

Ongoing regulatory oversight

The FDA continues to evaluate REMS effectiveness through:

Post-marketing safety data
manufacturer reporting
program assessments

Manufacturers must regularly evaluate whether the REMS successfully mitigates risks.

When Does the FDA Require REMS?

The FDA does not require REMS for most medicines.

Instead, the agency applies REMS selectively to drugs with specific safety risks that cannot be managed through labeling alone.

Examples of risk scenarios include:

Teratogenic drugs that cause birth defects
Opioids with high abuse potential
Oncology treatments with severe toxicity
Psychiatric medicines with suicide risks

These programs help regulators maintain access to critical therapies while protecting patients.

Components of a REMS Program

REMS programs vary widely depending on the drug’s risk profile. However, the FDA recognizes several core components.

Medication Guides

Medication Guides provide FDA-approved patient information explaining:

Drug benefits
Safety risks
Proper usage instructions

Pharmacists must distribute these guides whenever patients receive the medication.

Medication Guides improve patient awareness and encourage safe use.

Communication Plans

Some REMS programs include communication plans that inform healthcare professionals about drug risks.

These plans may involve:

Dear Healthcare Provider letters
educational materials
risk-communication campaigns

Communication plans ensure clinicians understand safety requirements.

Elements to Assure Safe Use (ETASU)

For drugs with particularly serious risks, the FDA requires Elements to Assure Safe Use (ETASU).

These elements may require:

Provider certification before prescribing
Pharmacy certification before dispensing
Patient enrollment in monitoring programs
Laboratory tests prior to dispensing medication

Approximately 90% of active REMS programs include ETASU requirements, reflecting their importance in managing serious risks.

Implementation Systems

Pharmaceutical manufacturers must build systems that enforce REMS requirements.

These systems often include:

secure data platforms
patient registries
distribution controls
compliance monitoring

Manufacturers must also maintain records demonstrating compliance.

REMS Assessment

Companies must regularly evaluate the effectiveness of their REMS programs.

Assessments typically measure:

healthcare provider compliance
patient understanding of risks
safety outcomes

These evaluations help regulators determine whether modifications are necessary.

Types of REMS Programs

REMS programs fall into several structural categories.

Individual REMS

An individual REMS applies to a single drug product.

The manufacturer designs and manages the risk-mitigation program independently.

Examples include programs associated with drugs that carry unique safety risks.

Shared System REMS

Some drugs share a common REMS system across multiple manufacturers.

Shared systems promote:

efficiency
consistency
lower administrative burden

They often occur when several companies market similar drugs with identical safety risks.

Examples of REMS Programs

Several well-known drugs operate under REMS programs.

Isotretinoin

The acne medication isotretinoin carries a high risk of severe birth defects.

The iPLEDGE REMS program requires:

pregnancy testing
patient enrollment
strict prescribing controls

These measures prevent fetal exposure.

Opioid analgesics

Prescription opioids represent one of the most widely known REMS programs.

The Opioid Analgesic REMS requires education for healthcare providers treating patients with pain.

The program supports national efforts to reduce:

misuse
addiction
overdose deaths

Antipsychotic medicines

Some long-acting antipsychotics require REMS due to rare but serious adverse events.

For example, a schizophrenia medication may require administration only in certified healthcare settings that can monitor patients for several hours after injection.

These safeguards allow early detection of severe reactions.

Operational Responsibilities for Pharmaceutical Companies

REMS programs impose extensive operational responsibilities on drug manufacturers.

Program design

Manufacturers must collaborate with the FDA to design REMS strategies tailored to specific safety risks.

This process involves:

risk analysis
stakeholder consultation
system design

Companies must submit detailed REMS documentation during drug approval or post-approval review.

Implementation and infrastructure

Implementing REMS programs requires substantial infrastructure.

Companies may need to build:

digital patient registries
provider certification systems
distribution tracking platforms
educational portals

These systems ensure compliance with regulatory requirements.

Monitoring and reporting

Manufacturers must track REMS performance using data such as:

prescribing behavior
patient enrollment numbers
safety outcomes

Regular reporting ensures regulators receive accurate program data.

Compliance Challenges in REMS Programs

Although REMS programs improve safety, they also introduce operational complexity.

Administrative burden

Healthcare providers often report administrative challenges associated with REMS requirements.

Common issues include:

documentation requirements
certification processes
patient monitoring obligations

These administrative tasks can create barriers to treatment access.

Access limitations

Strict REMS requirements may reduce the number of providers able to prescribe certain drugs.

This limitation can affect patients in rural or underserved areas.

For example, therapies requiring specialized monitoring may only be available in certified healthcare centers.

Operational costs

Pharmaceutical companies must invest significant resources to implement REMS infrastructure.

These costs may include:

software development
data management systems
compliance monitoring teams

Despite these costs, regulators consider REMS programs essential for patient safety.

Measuring REMS Effectiveness

The FDA requires manufacturers to evaluate whether REMS programs achieve their intended safety goals.

Key performance metrics

Typical evaluation metrics include:

patient adherence to monitoring requirements
healthcare provider knowledge of risks
incidence of adverse events

These data help regulators determine whether the program reduces safety risks.

Program modifications

If assessments reveal gaps, the FDA may require modifications.

For example, regulators may:

add additional monitoring requirements
expand provider education
adjust distribution controls

These modifications ensure REMS programs remain effective.

Emerging Trends in REMS Regulation

The REMS landscape continues to evolve.

Simplification initiatives

In some cases, regulators remove REMS requirements once safety risks become manageable through labeling alone.

For example, the FDA recently removed REMS requirements for certain CAR-T cancer therapies after concluding that existing warnings adequately address safety risks.

This change reflects regulators’ willingness to adjust risk-management strategies as evidence evolves.

Increased transparency

The FDA launched a public dashboard providing data on REMS programs, including program counts and modifications.

These tools allow researchers and healthcare professionals to analyze REMS data more easily.

Integration with pharmacovigilance systems

REMS programs increasingly integrate with broader pharmacovigilance systems that track adverse drug events.

These systems support:

early safety signal detection
real-world risk monitoring
improved regulatory decision-making

Global Perspectives on Risk Management

Although REMS represents a uniquely American regulatory program, other regions use similar safety frameworks.

For example:

The European Union requires Risk Management Plans (RMPs) for new medicines.
Japan and other countries maintain post-marketing surveillance systems.

These frameworks share a common goal: managing drug risks after approval.

However, REMS programs often impose more targeted and restrictive safety controls.

Best Practices for REMS Compliance

Pharmaceutical companies can adopt several strategies to manage REMS programs effectively.

Build cross-functional teams

Successful REMS implementation requires collaboration across:

regulatory affairs
pharmacovigilance
compliance
medical affairs
IT systems

These teams ensure consistent oversight.

Develop robust digital systems

Automated platforms simplify REMS management.

Effective systems should support:

patient enrollment
provider certification
data collection
reporting

Technology reduces administrative burden and improves compliance.

Engage healthcare providers

Healthcare professionals play a central role in REMS compliance.

Companies should provide:

clear educational materials
training resources
technical support

Effective education improves program adoption.

Monitor performance continuously

Companies should track REMS metrics proactively rather than waiting for regulatory assessments.

Continuous monitoring allows early identification of potential issues.

The Future of REMS Programs

Several trends will shape the next generation of REMS programs.

Digital health integration

Electronic health records may automate REMS requirements such as:

patient monitoring alerts
prescribing restrictions
laboratory test verification

Automation could reduce administrative burden.

Real-world evidence

Regulators increasingly rely on real-world data to evaluate drug safety.

These data sources include:

healthcare databases
insurance claims
electronic medical records

Real-world evidence may inform future REMS modifications.

Risk-based regulation

Regulators continue refining risk-based oversight.

Some REMS programs may become less restrictive as safety knowledge improves.

Others may incorporate new monitoring tools.

Conclusion

Risk Evaluation and Mitigation Strategies represent one of the FDA’s most important tools for managing medication safety after approval.

By combining education, monitoring, and distribution controls, REMS programs help ensure that high-risk medicines remain available to patients who need them while minimizing preventable harm.

More than 300 REMS programs have been implemented since 2008, and dozens remain active today. These programs require substantial coordination among regulators, pharmaceutical companies, healthcare professionals, and patients.

As drug development grows increasingly complex—particularly in areas such as oncology, gene therapy, and personalized medicine—risk-management frameworks like REMS will remain essential for balancing innovation with patient safety.

For pharmaceutical companies, effective REMS compliance demands strong governance, digital infrastructure, and continuous monitoring. Organizations that invest in these capabilities can navigate regulatory expectations while maintaining patient access to life-saving therapies.

References

U.S. Food and Drug Administration – Risk Evaluation and Mitigation Strategies Overview
https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
FDA REMS Public Dashboard
https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/risk-evaluation-and-mitigation-strategy-rems-public-dashboard
REMS program statistics and overview
https://medx.it.com/how-many-rems-are-there-a-deep-dive-into-fdas-safety-programs
REMS framework and ETASU requirements
https://link.springer.com/article/10.1007/s40264-025-01542-9
FDA Office of Surveillance and Epidemiology Annual Report
https://fda.report/media/157388/2021%2BOSE%2BAnnual%2BReport%2B4-2-2022.pdf
Opioid Analgesic REMS Program
https://www.fda.gov/drugs/information-drug-class/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems
Overview of REMS Programs
https://en.wikipedia.org/wiki/Risk_Evaluation_and_Mitigation_Strategies
Reuters report on removal of REMS for CAR-T therapies
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-eliminates-risk-evaluation-mitigation-strategies-car-t-cancer-therapies-2025-06-27/